GlassScriptPhysician profile
Ghayathri Ananthi Devaraj
NPI 1376990796
$2,220.81
in general payments reported to CMS, 2019-2025
21 companies · $92.44 in 2025
The $92.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $483 · 2023: $664 · 2024: $805 · 2025: $92.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.89 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $427.15 | 2021-2024 | |
| Novo Nordisk INC | $183.78 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.21 | 2023-2025 | Jardiance |
| Abbott Laboratories | $154.22 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $150.28 | 2022-2024 | Farxiga, Flumist Quadrivalent, Airsupra |
| Exact Sciences Corporation | $150.27 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $139.90 | 2024 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $135.26 | 2023-2024 | |
| Lilly USA, LLC | $122.40 | 2022-2024 | Jardiance, Mounjaro |
| Phadia US INC. | $87.60 | 2021-2023 | Immunocap |
| Merck Sharp & Dohme LLC | $86.56 | 2021-2023 | M-M-R II, Gardasil 9, Rotateq |
| Genentech USA, INC. | $74.94 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $60.17 | 2022 | |
| Dexcom, INC. | $53.87 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $46.73 | 2023-2024 | Otezla, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $46.19 | 2021-2023 | Doc Band |
| Sanofi-Aventis U.S. LLC | $43.03 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $32.18 | 2024 | Rexulti |
| Medtronic, INC. | $30.90 | 2023-2024 | Minimed 780g |
| Sanofi Pasteur INC. | $17.85 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghayathri Devaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.